Mary Jo Villar
Hematology & Oncology · Hialeah, FLNPI 1003804287
Payments from drug & device makers
Across 103 payments — averaging $76.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Avyxa Pharma, LLC$3K
- Johnson & Johnson$1K
- E.r. Squibb & Sons, L.L.C.$522
- Incyte Corporation$519
- AstraZeneca$479
- Pharmacyclics LLC, An Abbvie Company$331
- plus $2K from 20 others
What the payments were for
- Speaking & faculty fees$2,00025%
- Travel & lodging$3414%
- Food & beverage$5,07864%
- Education$4976%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Avyxa Pharma, LLC | 4 | $2,608 |
| Johnson & Johnson(2 entities) | 24 | $1,054 |
| E.r. Squibb & Sons, L.L.C. | 5 | $522 |
| Incyte Corporation | 6 | $519 |
| AstraZeneca | 4 | $479 |
| Pharmacyclics LLC, An Abbvie Company | 15 | $331 |
| Regeneron Healthcare Solutions, Inc. | 4 | $269 |
| Merck | 5 | $192 |
| AbbVie | 8 | $192 |
| Seagen Inc. | 2 | $168 |
| Medtronic | 2 | $162 |
| Beigene USA, Inc. | 3 | $150 |
| Bristol Myers Squibb | 6 | $126 |
| Dova Pharmaceuticals | 1 | $125 |
| Clovis Oncology, Inc. | 1 | $125 |
| Ferring Pharmaceuticals Inc. | 1 | $125 |
| EMD Serono, Inc. | 1 | $122 |
| Bayer | 1 | $122 |
| Pfizer | 1 | $121 |
| Janssen Scientific Affairs, LLC | 1 | $104 |
| Eisai Inc. | 1 | $102 |
| Blue Earth Diagnostics | 1 | $90 |
| Daiichi Sankyo Inc. | 3 | $56 |
| Sumitomo Pharma America, Inc. | 1 | $25 |
| Beone Medicines USA, Inc. | 1 | $15 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,916 in reported general payments places this provider in the 40th percentile of 694 hematology & oncology providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 42 | $572,660 |
| RevlimidLenalidomide | 38 | $445,087 |
| CabometyxCabozantinib S-Malate | 19 | $252,684 |
| IbrancePalbociclib | 15 | $238,393 |
| LeukeranChlorambucil | 18 | $219,972 |
| ImbruvicaIbrutinib | 16 | $199,791 |
| ErleadaApalutamide | 18 | $194,880 |
| PromactaEltrombopag Olamine | 12 | $172,038 |
| BrukinsaZanubrutinib | 11 | $165,726 |
| JakafiRuxolitinib Phosphate | 15 | $158,020 |
| VerzenioAbemaciclib | 16 | $132,069 |
| XtandiEnzalutamide | 16 | $124,887 |
| VenclextaVenetoclax | 14 | $68,848 |
| Abiraterone Acetate | 56 | $5,069 |
| Exemestane | 94 | $2,027 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $126 | $445,08738 claims |
| PfizerIbrance | $121 | $238,39315 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $331 | $199,79116 claims |
| Johnson & JohnsonErleada | $1,054 | $194,88018 claims |
| Beigene USA, Inc.Brukinsa | $150 | $165,72611 claims |
| Incyte CorporationJakafi | $519 | $158,02015 claims |
| AbbVieVenclexta | $192 | $68,84814 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $104 | $5,06956 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 694 hematology & oncology providers in Florida.
Other hematology & oncology in Hialeah
- Carl LandgrenMiami$47.8M
- Julio ChavezTampa$16.4M
- Steven AttiaJacksonville$13.9M
- Santosh NairOrange City$13.5M
- Frederick LockeTampa$12.8M
- Tarek MekhailOrlando$11.2M
- Carlos AlemanyOrlando$10.9M
- Thomas GeorgeGainesville$10.3M
- Sikander AilawadhiJacksonville$9.8M
- Richard KimTampa$8.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.